Rainbow Coral (RBCC) 10-Q/A 10 Dec 14 2015 Q2 Quarterly report (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	6 Months Ended
	Sep. 30, 2014	Nov. 15, 2014
Document and Entity Information [Abstract]	'	'
Document Type	'10-Q	'
Amendment Flag	'false	'
Document Period End Date	30-Sep-14	'
Entity Registrant Name	'Rainbow Coral Corp.	'
Entity Central Index Key	'0001499790	'
Current Fiscal Year End Date	'--03-31	'
Document Fiscal Period Focus	'Q2	'
Document Fiscal Year Focus	'2015	'
Entity Filer Category	'Smaller Reporting Company	'
Entity Units Outstanding	'	33,134,943

CONSOLIDATED_BALANCE_SHEETS

CONSOLIDATED BALANCE SHEETS (USD $)	Sep. 30, 2014	Mar. 31, 2014
CURRENT ASSETS	'	'
Cash and cash equivalents	$17,863	$65,373
Prepaid expenses	5,244	841
Inventory	3,951	5,249
Total current assets	27,058	71,463
Fixed assets, net of accumulated depreciation of $10,135 and $7,615, respectively	3,762	6,282
TOTAL ASSETS	30,820	77,745
CURRENT LIABILITIES	'	'
Accounts payable and accrued expenses	283,422	191,780
Advances payable	'	149,453
Related party advances payable	142,509	131,505
Current portion of notes payable	9,311	2,843
Total current liabilities	435,242	475,581
Convertible notes payable, net of discount of $281,923 and $215,716, respectively	10,643	13,111
Notes payable	45,349	47,157
Accrued interest payable	9,040	11,201
TOTAL LIABILITIES	500,274	547,050
COMMITMENTS AND CONTINGENCIES	'	'
STOCKHOLDERS' DEFICIT	'	'
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at September 30, 2014 and March 31, 2014, respectively	'	'
Common stock, $0.0001 par value; 250,000,000 shares authorized; 28,934,943 and 22,851,900 shares issued and outstanding at September 30, 2014 and March 31, 2014, respectively	2,893	2,285
Additional paid-in capital	2,996,245	2,460,965
Accumulated deficit	-3,468,592	-2,932,555
Total stockholders' deficit	-469,454	-469,305
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$30,820	$77,745

CONSOLIDATED_BALANCE_SHEETS_Pa

CONSOLIDATED BALANCE SHEETS (Parentheticals) (USD $)	Sep. 30, 2014	Mar. 31, 2014
CONSOLIDATED BALANCE SHEETS [Abstract]	'	'
Accumulated depreciation	$10,135	$7,615
Noncurrent convertible notes payable discount	$281,923	$215,716
Preferred Stock, par value per share	$0.00	$0.00
Preferred Stock, shares authorized	10,000,000	10,000,000
Preferred Stock, shares issued	0	0
Preferred Stock, shares outstanding	0	0
Common Stock, par value per share	$0.00	$0.00
Common Stock, shares authorized	250,000,000	250,000,000
Common Stock, shares issued	28,934,943	22,851,900
Common Stock, shares outstanding	28,934,943	22,851,900

CONSOLIDATED_STATEMENTS_OF_OPE

CONSOLIDATED STATEMENTS OF OPERATIONS (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
CONSOLIDATED STATEMENTS OF OPERATIONS [Abstract]	'	'	'	'
REVENUE	$36,174	$33,971	$71,321	$58,553
COST OF GOODS SOLD	20,452	17,068	37,735	34,876
GROSS PROFIT	15,722	16,903	33,586	23,677
OPERATING EXPENSES	'	'	'	'
Expenses related to joint ventures and business development activities	20,000	48,125	60,000	55,000
General and administrative expenses	141,246	123,188	270,931	255,944
LOSS FROM OPERATIONS	-145,524	-154,410	-297,345	-287,267
OTHER EXPENSE	'	'	'	'
Interest expense	-15,604	-94,167	-238,692	-180,679
NET LOSS	($161,128)	($248,577)	($536,037)	($467,946)
NET LOSS PER COMMON SHARE - Basic and diluted	($0.01)	($0.01)	($0.02)	($0.03)
WEIGHTED AVERAGE NUMBER OF COMMON SHARES OUTSTANDING - Basic and diluted	28,867,632	16,631,937	27,288,604	15,525,134

CONSOLIDATED_STATEMENT_OF_CHAN

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT (USD $)	Total	Common Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]
BALANCE at Mar. 31, 2014	($469,305)	$2,285	$2,460,965	($2,932,555)
BALANCE, SHARES at Mar. 31, 2014	22,851,900	22,851,900	'	'
Shares issued for conversion of notes payable	243,322	608	242,714	'
Shares issued for conversion of notes payable, shares	6,083,043	6,083,043	'	'
Discount on issuance of convertible notes payable	292,566	'	292,566	'
Net loss	-536,037	'	'	-536,037
BALANCE at Sep. 30, 2014	($469,454)	$2,893	$2,996,245	($3,468,592)
BALANCE, SHARES at Sep. 30, 2014	28,934,943	28,934,943	'	'

CONSOLIDATED_STATEMENTS_OF_CAS

CONSOLIDATED STATEMENTS OF CASH FLOWS (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
CASH FLOW FROM OPERATING ACTIVITIES:	'	'
Net loss	($536,037)	($467,946)
Adjustments to reconcile net loss to net cash used in operating activities:	'	'
Amortization of discount on convertible notes payable	226,359	170,465
Depreciation	2,520	2,172
Changes in operating assets and liabilities:	'	'
Inventory	1,298	'
Prepaid expenses	-4,403	'
Accounts payable and accrued liabilities	91,642	-29,908
Accrued interest payable	12,334	10,214
NET CASH USED IN OPERATING ACTIVITIES	-206,287	-315,003
CASH FLOWS FROM FINANCING ACTIVITIES	'	'
Proceeds from advances	143,113	283,229
Proceeds from related party advances	11,004	28,509
Repayments of related party advances	'	-1,686
Proceeds from notes payable	4,660	'
NET CASH PROVIDED BY FINANCING ACTIVITIES	158,777	310,052
NET DECREASE IN CASH	-47,510	-4,951
CASH, at the beginning of the period	65,373	84,592
CASH, at the end of the period	17,863	79,641
Supplemental Disclosures of Cash Flow Information:	'	'
Cash paid during the period for: Interest	'	'
Cash paid during the period for: Taxes	'	'
Noncash investing and financing activities:	'	'
Refinance of advances into convertible notes payable	292,566	416,685
Beneficial conversion discount on convertible notes	292,566	416,685
Conversion of convertible notes and interest into common stock	$243,322	$200,113

General_Organization_and_Busin

General Organization and Business	6 Months Ended
	Sep. 30, 2014
General Organization and Business [Abstract]	'
General Organization and Business	'
	Note 1. General Organization and Business
	RAINBOW CORAL CORP. (the “Company”), a Florida corporation, was formed to build a coral farm facility to develop and propagate (or grow) live coral, independent of the oceans, as a future farm reserve against the decline of natural wild reefs. We intend to grow, harvest and distribute as many varieties of hard and soft sizes as possible of captive-bred corals that are attractive, to as many consumers as possible who can maintain them in a healthy ecosystem aquarium. We believe that coral and other marine aquarium livestock should be supplied by farms or captive breeders, rather than removed from the natural reefs. The additional uses for coral as a source of potential leading edge medical discoveries are an attractive opportunity for the Company's coral farming activity. We believe that the world of bio-research is a natural continuation of our core coral propagation business. Accordingly on October 23, 2011, the Company formed a subsidiary, Rainbow Biosciences, LLC to look into the opportunities within the bioscience market. Rainbow Biosciences, LLC will continue to research opportunities into the bioscience markets.
	The Company was incorporated on August 13, 2010 with its corporate headquarters located in Miramar Beach, Florida.  The Company's fiscal year end is March 31.
	Joint Ventures
	On March 13, 2012, the Company entered into a stock purchase agreement (“N3D Stock Purchase Agreement”) with Nano3D Biosciences, Inc. (“N3D”), a Texas corporation that has developed a unique concept in three dimensional cell research tools. Under the terms of the N3D Stock Purchase Agreement, the Company agreed to acquire 604 shares of common stock of N3D, representing approximately 5% of the outstanding shares on the date of the agreement, for a price of $413.62 per share. The total purchase price of $249,826 was to be paid by making weekly payments of $5,000 until fully paid. Under the terms of the N3D Stock Purchase Agreement, we could discontinue payment of the purchase price at any time by providing written notice to N3D. The Company invested $60,000 in N3D resulting in the acquisition of 145 shares of N3D's common stock. The Company discontinued payments to N3D in May 2012 because of their delay in reaching certain milestones in the commercialization process.  The Company wrote off the investment in full due to the uncertainty about whether the carrying amount is recoverable.  During the six months ended September 30, 2014, the Company paid and expensed $40,000 with N3D.
	On February 1, 2013, the Company entered into a joint venture agreement with TheraKine Ltd. (“TheraKine”) in order to explore potential business opportunities to exploit TheraKine's novel drug delivery technologies. TheraKine is the developer of a revolutionary, sustained-release drug delivery platform that could soon make local delivery of biologic agents and small molecules safer, more effective and more convenient than ever before. During the six months ended September 30, 2014, the Company paid and expensed $20,000 pursuant to this joint venture.

Going_Concern

Going Concern	6 Months Ended
	Sep. 30, 2014
Going Concern [Abstract]	'
Going Concern	'
	Note 2. Going Concern
	The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. For the six months ended September 30, 2014, the Company had a net loss of $536,037 and negative cash flow from operating activities of $206,287. As of September 30, 2014, the Company had negative working capital of $408,184. Management does not anticipate having positive cash flow from operations in the near future.
	These factors raise a substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the possible inability of the Company to continue as a going concern.
	The Company does not have the resources at this time to repay its credit and debt obligations, make any payments in the form of dividends to its shareholders or fully implement its business plan. Without additional capital, the Company will not be able to remain in business.
	Management has plans to address the Company's financial situation as follows:
	In the near term, management plans to continue to focus on raising the funds necessary to fully implement the Company's business plan. Management will continue to seek out debt financing to obtain the capital required to meet the Company's financial obligations. There is no assurance, however, that lenders will continue to advance capital to the Company or that the new business operations will be profitable. The possibility of failure in obtaining additional funding and the potential inability to achieve profitability raise doubts about the Company's ability to continue as a going concern.
	In the long term, management believes that the Company's projects and initiatives will be successful and will provide cash flow to the Company, which will be used to finance the Company's future growth. However, there can be no assurances that the Company's planned activities will be successful, or that the Company will ultimately attain profitability. The Company's long-term viability depends on its ability to obtain adequate sources of debt or equity funding to meet current commitments and fund the continuation of its business operations, and the ability of the Company to ultimately achieve adequate profitability and cash flows from operations to sustain its operations.

Summary_of_Significant_Account

Summary of Significant Accounting Policies	6 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Summary of Significant Accounting Policies	'
	Note 3. Summary of Significant Accounting Policies
	Basis of Presentation
	The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
	Interim Financial Statements
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended March 31, 2014 and notes thereto and other pertinent information contained in our Form 10-K filed with the Securities and Exchange Commission (the “SEC”).
	The results of operations for the six-month period ended September 30, 2014 are not necessarily indicative of the results to be expected for the full fiscal year ending March 31, 2015.
	Principles of Consolidation
	The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation.
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
	Cash and Cash Equivalents
	For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. Cash and cash equivalents were $17,863 and $65,373 at September 30, 2014 and March 31, 2014, respectively.
	Inventory
	Inventory represents aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence.
	Fixed Assets
	Fixed assets of the Company include vehicles and computer equipment and are stated at cost. Expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred.
	Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes.
	Impairment of long-lived assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the six months ended September 30, 2014.
	Revenue and cost recognition
	The Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances.
	Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products which have been sold.
	Advertising Costs
	The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $5,384 and $6,058 of advertising costs for the six months ended September 30, 2014 and September 30, 2013, respectively.
	Income Taxes
	The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2014 or March 31, 2014.
	Earnings (Loss) per Common Share
	The basic earnings (loss) per common share are calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity instruments. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Company's convertible debt is considered anti-dilutive due to the Company's net loss for the periods ended September 30, 2014 and 2013. As a result, for the periods ended September 30, 2014 and 2013, potentially issuable shares as a result of conversions of convertible notes payable have been excluded from the calculation. At September 30, 2014  and 2013, the Company had 16,471,845 and 11,439,232, respectively, potentially issuable shares upon the conversion of convertible notes payable and interest.
	Financial Instruments
	The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.
	Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
		Level 1 -	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
		Level 2 -	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		Level 3 -	Inputs that are both significant to the fair value measurement and unobservable.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
	Subsequent events
	The Company evaluated material events occurring between September 30, 2014 and through the date when the consolidated financial statements were available to be issued for disclosure consideration.
	Recently Issued Accounting Pronouncements
	Recently issued accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Advances

Advances	6 Months Ended
	Sep. 30, 2014
Advances [Abstract]	'
Advances	'
	Note 4. Advances
	During the six months ended September 30, 2014, the Company received advances from Vista View Ventures, Inc. in the amount of $143,113 for working capital. These advances are non-interest bearing and payable on demand. During the same period, the Company refinanced $292,566 of the advances into convertible notes payable with Vista View Ventures, Inc. As of September 30, 2014 and March 31, 2014, advances in the amount of $0 and $149,453, respectively, are included in current liabilities on the consolidated balance sheets.

Convertible_Notes_Payable

Convertible Notes Payable	6 Months Ended
	Sep. 30, 2014
Convertible Notes Payable [Abstract]	'
Convertible Notes Payable	'
	Note 5. Convertible Notes Payable
	Convertible notes payable to Vista View Ventures, Inc. consists of the following as of September 30, 2014 and March 31, 2014:
			30-Sep-14			31-Mar-14
	Convertible note payable, dated June 30, 2013, bearing interest at 10% per annum, matures on June 30, 2015 and convertible into shares of common stock at $0.04 per share		$	—		$	4,742
	Convertible note payable, dated September 30, 2013, bearing interest at 10% per annum, matures on September 30, 2015 and convertible into shares of common stock at $0.04 per share			—			224,085
	Convertible note payable, dated April , bearing interest at 10% per annum, matures on March 31, 2016 and convertible into shares of common stock at $0.03 per share			149,453			—
	Convertible note payable, dated June 30, 2014, bearing interest at 10% per annum, matures on June 30, 2016 and convertible into shares of common stock at $0.02 per share			62,980			—
	Convertible note payable, dated September 30, 2014, bearing interest at 10% per annum, matures on September 30, 2016 and convertible into shares of common stock at $0.01 per share			80,133			—
	Total convertible notes payable		$	292,566		$	228,827
	Less: current portion of convertible notes payable			—			—
	Less: discount on convertible notes payable			-281,923			-215,716
	Convertible notes payable, net of discount		$	10,643		$	13,111
	All principal along with accrued interest is payable on the maturity dates.
	Convertible notes issued
	During the six months ended September 30, 2014, the Company signed convertible promissory notes of $292,566 in total with Vista View Ventures Inc., which refinanced non-interest bearing advances. These notes are payable at maturity and bear interest at 10% per annum. The holder of the notes may not convert the convertible promissory note into common stock if that conversion would result in the holder owing more than 4.99% of the number of shares of common stock outstanding on the conversion date. The convertible promissory notes are convertible into common stock at rates of between $0.03 and $0.01 per share at the option of the holder.
	Date Issued	Maturity Date		Interest Rate		Conversion Rate		Amount of Note
	1-Apr-14	31-Mar-16		10	%	$	0.03	$	149,453
	30-Jun-14	30-Jun-16		10	%	$	0.02		62,980
	30-Sep-14	30-Sep-16		10	%	$	0.01		80,133
	Total							$	292,566
	The Company evaluated the terms of the notes in accordance with ASC Topic No. 815 – 40, Derivatives and Hedging - Contracts in Entity's Own Stock and determined that the underlying common stock is indexed to the Company's common stock. The Company determined that the conversion features did not meet the definition of a liability and therefore did not bifurcate the conversion feature and account for it as a separate derivative liability. The Company evaluated the conversion features for a beneficial conversion feature. The effective conversion price was compared to the market price on the date of the notes and was deemed to be less than the market value of underlying common stock at the inception of the note. Therefore, the Company recognized a discount for the beneficial conversion feature in the amount of $292,566, in aggregate, on the date the notes were signed. The beneficial conversion feature was recorded as an increase in additional paid-in capital and a discount to the convertible notes payable. The discount to the convertible notes payable will be amortized to interest expense over the life of the notes. The Company amortized $226,359 of the discount on the convertible notes payable to interest expense during the six months ended September 30, 2014.
	Conversions to Common Stock
	During six months ended September 30, 2014, the holders of the convertible note payable dated June 30, 2013 elected to convert principal of $4,742 and accrued interest of $212 into shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense.
	During six months ended September 30, 2014, the holders of the convertible note payable dated September 30, 2013 elected to convert principal of $224,085 and accrued interest of $14,283 into shares of common stock of the Company. On the conversion date, the unamortized discount related to the principal amount converted was immediately amortized to interest expense.

Notes_payable

Notes payable	6 Months Ended
	Sep. 30, 2014
Notes payable [Abstract]	'
Notes payable	'
	Note 6. Notes payable
	On December 30, 2013, the Company entered into a promissory note for $50,000 with a third party bearing interest at 5% per annum.  Under the terms of the note payable, the Company is required to make monthly payments on the note payable on January 1, 2015 over a period of 4 years. At September 30, 2014 and March 31, 2014, the Company owed the noteholder $49,660 and $50,000, respectively.
	During the nine months ended September 30, 2014, the Company entered into a promissory note for $5,000 with a third party bearing interest at 5% per annum.  Under the terms of the note payable, the Company is required to repay the note in 26 equal monthly installments beginning in October 2014. At September 30, 2014 the Company owed the note holder $5,000.

Related_Party_Transactions

Related Party Transactions	6 Months Ended
	Sep. 30, 2014
Related Party Transactions [Abstract]	'
Related Party Transactions	'
	Note 7. Related Party Transactions.
	As of September 30, 2014 and March, 31, 2014, related party advances payable totaled $142,509 and $131,505. Transactions consisted solely of advances payable to Mr. Foxwell for amounts advanced to Father Fish, its wholly-owned subsidiary, for working capital.

Stockholders_Equity

Stockholders' Equity	6 Months Ended
	Sep. 30, 2014
Stockholders' Equity [Abstract]	'
Stockholders' Equity	'
	Note 8. Stockholders' Equity
	During six months ended September 30, 2014, the holders of our convertible notes elected to convert principal and interest of $243,322 into 6,083,043 shares of common stock.

Commitments

Commitments	6 Months Ended
	Sep. 30, 2014
Commitments [Abstract]	'
Commitments	'
	Note 9. Commitments
	The Company has an arrangement with a third party whereby the third party provides the Company with office space, legal services, accounting services, fundraising and management services.  During the six months ending September 30, 2014, the Company incurred $95,637 of fees related to the third party.  At September 30, 2014, the Company owes the third party $253,177, which is recorded in accounts payable and accrued expenses.

Business_Segments

Business Segments	6 Months Ended
	Sep. 30, 2014
Business Segments [Abstract]	'
Business Segments	'
	Note 10. Business Segments
	The Company has two reportable operating segments: (1) aquarium and aquarium supplies and (2) medical technology. These reportable segments are managed separately due to differences in their products.
	The only segment which generates revenue is aquarium and aquarium supplies. Management evaluates and monitors performance of this segment primarily through, among other measures, gross profit. The medical technology segment is in the development stage and has not begun to generate revenue.
	The results of operations and financial position of the two reportable operating segments and corporate were as follows:
	Results of Operations:
		Six months ended					Three months ended
		September 30,					September 30,
		2014			2013		2014		2013
	REVENUE
	Aquarium and aquarium supplies	$	71,321		$	58,553	$	36,174	$	33,971
	Medical technology		—			—		—		—
	Corporate		—			—		—		—
		$	71,321		$	58,553	$	36,174	$	33,971
	GROSS PROFIT
	Aquarium and aquarium supplies	$	33,586		$	23,677	$	15,722	$	16,903
	Medical technology		—			—		—		—
	Corporate		—			—		—		—
		$	33,586		$	23,677	$	15,722	$	16,903
	GENERAL AND ADMINISTRATIVE EXPENSE
	Aquarium and aquarium supplies	$	59,474		$	51,677	$	31,696	$	8,928
	Corporate		211,457			204,267		109,550		114,260
		$	270,931		$	255,944	$	141,246	$	123,188
	Corporate operating expense includes general and administrative costs not allocated to operating segments.
				30-Sep-14			31-Mar-14
	TOTAL ASSETS
	Aquarium and aquarium supplies			$	9,070		$	24,756
	Medical technology				—			—
	Corporate				21,750			52,989
				$	30,820		$	77,745

Subsequent_Events

Subsequent Events	6 Months Ended
	Sep. 30, 2014
Subsequent Events [Abstract]	'
Subsequent Events	'
	Note 11. Subsequent Events
	During October 2014, the holders of the convertible promissory note dated April 1, 2014 elected to convert principal and interest in the amount of $126,000 into 4,200,000 shares of the Company's common stock, at a rate of $0.03 per share.

Summary_of_Significant_Account1

Summary of Significant Accounting Policies (Policy)	6 Months Ended
	Sep. 30, 2014
Summary of Significant Accounting Policies [Abstract]	'
Basis of Presentation	'
	Basis of Presentation
	The consolidated financial statements and related disclosures have been prepared pursuant to the rules and regulations of the SEC. The financial statements have been prepared using the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America (“GAAP”).
Interim Financial Statements	'
	Interim Financial Statements
	The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles in the United States of America (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, the consolidated financial statements do not include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. These consolidated financial statements should be read in conjunction with the consolidated financial statements for the fiscal year ended March 31, 2014 and notes thereto and other pertinent information contained in our Form 10-K filed with the Securities and Exchange Commission (the “SEC”).
	The results of operations for the six-month period ended September 30, 2014 are not necessarily indicative of the results to be expected for the full fiscal year ending March 31, 2015.
Principles of Consolidation	'
	Principles of Consolidation
	The consolidated financial statements include the accounts and operations of Rainbow Coral Corp., and its wholly owned subsidiaries, Rainbow Biosciences, LLC and Father Fish Aquarium, Inc. (collectively referred to as the “Company”). All material intercompany accounts and transactions have been eliminated in consolidation.
Use of Estimates	'
	Use of Estimates
	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Actual results could differ from those estimates.
Cash and Cash Equivalents	'
	Cash and Cash Equivalents
	For the purpose of the financial statements, cash equivalents include all highly liquid investments with maturity of three months or less. Cash and cash equivalents were $17,863 and $65,373 at September 30, 2014 and March 31, 2014, respectively.
Inventory	'
	Inventory
	Inventory represents aquarium products and other pet supply items valued at the lower of cost or net realizable value determined using the weighted average cost method, and with market defined as the lower of replacement cost or realizable value. The cost of inventory includes all costs to purchase, costs of conversion and other costs incurred in bringing the inventory to its present location and condition. Inventory is reduced for the estimated losses due to obsolescence.
Fixed Assets	'
	Fixed Assets
	Fixed assets of the Company include vehicles and computer equipment and are stated at cost. Expenditures for fixed assets that substantially increase the useful lives of existing assets are capitalized at cost and depreciated. Routine expenditures for repairs and maintenance are expensed as incurred.
	Depreciation is provided principally on the straight-line method over the estimated useful lives of three to five years for financial reporting purposes.
Impairment of long-lived assets	'
	Impairment of long-lived assets
	Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the long-lived asset may not be recoverable. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the undiscounted cash flows expected to result from the use and eventual disposition of the asset. If it is determined that an impairment loss has occurred, the loss is measured as the amount by which the carrying amount of the long-lived asset exceeds its fair value. The Company determined that there was no impairment of long-lived assets during the six months ended September 30, 2014.
Revenue and Cost Recognition	'
	Revenue and cost recognition
	The Company recognizes revenue when persuasive evidence of an arrangement exists, product delivery has occurred or the services have been rendered, the price is fixed or determinable and collectability is reasonably assured. Revenue is generated from the sales of live coral and other related products in a retail setting. Revenue is recognized net of sales returns and allowances.
	Costs of goods sold represents product costs associated with generating revenue. It includes all costs of purchase, costs of conversion and other costs of acquiring products which have been sold.
Advertising Costs	'
	Advertising Costs
	The Company's policy regarding advertising is to expense advertising costs as incurred. The Company incurred $5,384 and $6,058 of advertising costs for the six months ended September 30, 2014 and September 30, 2013, respectively.
Income Taxes	'
	Income Taxes
	The Company accounts for income taxes under ASC 740 Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. No deferred tax assets or liabilities were recognized as of September 30, 2014 or March 31, 2014.
Earnings (Loss) per Common Share	'
	Earnings (Loss) per Common Share
	The basic earnings (loss) per common share are calculated by dividing the Company's net income available to common shareholders by the weighted average number of common shares outstanding during the year. The diluted earnings (loss) per common share are calculated by dividing the Company's net income (loss) available to common shareholders by the diluted weighted average number of shares outstanding during the year. The diluted weighted average number of shares outstanding is the basic weighted number of shares adjusted as of the first of the year for any potentially dilutive debt or equity instruments. In periods in which a net loss has been incurred, all potentially dilutive common shares are considered anti-dilutive and thus are excluded from the calculation. The Company's convertible debt is considered anti-dilutive due to the Company's net loss for the periods ended September 30, 2014 and 2013. As a result, for the periods ended September 30, 2014 and 2013, potentially issuable shares as a result of conversions of convertible notes payable have been excluded from the calculation. At September 30, 2014  and 2013, the Company had 16,471,845 and 11,439,232, respectively, potentially issuable shares upon the conversion of convertible notes payable and interest.
Financial Instruments	'
	Financial Instruments
	The Company's balance sheet includes certain financial instruments. The carrying amounts of current assets and current liabilities approximate their fair value because of the relatively short period between the origination of these instruments and their expected realization.
	Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) 820 Fair Value Measurements and Disclosures (ASC 820) defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. ASC 820 also establishes a fair value hierarchy that distinguishes between (1) market participant assumptions developed based on market data obtained from independent sources (observable inputs) and (2) an entity's own assumptions about market participant assumptions developed based on the best information available in the circumstances (unobservable inputs). The fair value hierarchy consists of three broad levels, which gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1) and the lowest priority to unobservable inputs (Level 3). The three levels of the fair value hierarchy are described below:
		Level 1 -	Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities.
		Level 2 -	Inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly, including quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; inputs other than quoted prices that are observable for the asset or liability (e.g., interest rates); and inputs that are derived principally from or corroborated by observable market data by correlation or other means.
		Level 3 -	Inputs that are both significant to the fair value measurement and unobservable.
	Fair value estimates discussed herein are based upon certain market assumptions and pertinent information available to management as of September 30, 2014. The respective carrying value of certain on-balance-sheet financial instruments approximated their fair values due to the short-term nature of these instruments. These financial instruments include accounts payable, and accrued expenses. The fair value of the Company's notes payable is estimated based on current rates that would be available for debt of similar terms that is not significantly different from its stated value.
Subsequent events	'
	Subsequent events
	The Company evaluated material events occurring between September 30, 2014 and through the date when the consolidated financial statements were available to be issued for disclosure consideration.
Recently Issued Accounting Pronouncements	'
	Recently Issued Accounting Pronouncements
	Recently issued accounting pronouncements are not expected to, or did not have, a material impact on our financial position, results of operations or cash flows.

Convertible_Notes_Payable_Tabl

Convertible Notes Payable (Tables)	6 Months Ended
	Sep. 30, 2014
Convertible Notes Payable [Abstract]	'
Schedule of Convertible Notes Payable	'
	Convertible notes payable to Vista View Ventures, Inc. consists of the following as of September 30, 2014 and March 31, 2014:
			30-Sep-14			31-Mar-14
	Convertible note payable, dated June 30, 2013, bearing interest at 10% per annum, matures on June 30, 2015 and convertible into shares of common stock at $0.04 per share		$	—		$	4,742
	Convertible note payable, dated September 30, 2013, bearing interest at 10% per annum, matures on September 30, 2015 and convertible into shares of common stock at $0.04 per share			—			224,085
	Convertible note payable, dated April , bearing interest at 10% per annum, matures on March 31, 2016 and convertible into shares of common stock at $0.03 per share			149,453			—
	Convertible note payable, dated June 30, 2014, bearing interest at 10% per annum, matures on June 30, 2016 and convertible into shares of common stock at $0.02 per share			62,980			—
	Convertible note payable, dated September 30, 2014, bearing interest at 10% per annum, matures on September 30, 2016 and convertible into shares of common stock at $0.01 per share			80,133			—
	Total convertible notes payable		$	292,566		$	228,827
	Less: current portion of convertible notes payable			—			—
	Less: discount on convertible notes payable			-281,923			-215,716
	Convertible notes payable, net of discount		$	10,643		$	13,111
Schedule of Convertible Notes Issued	'
	Date Issued	Maturity Date		Interest Rate		Conversion Rate		Amount of Note
	1-Apr-14	31-Mar-16		10	%	$	0.03	$	149,453
	30-Jun-14	30-Jun-16		10	%	$	0.02		62,980
	30-Sep-14	30-Sep-16		10	%	$	0.01		80,133
	Total							$	292,566

Business_Segments_Tables

Business Segments (Tables)	6 Months Ended
	Sep. 30, 2014
Business Segments [Abstract]	'
Schedule of Results of Operations by Reporting Segment	'
	The results of operations and financial position of the two reportable operating segments and corporate were as follows:
	Results of Operations:
		Six months ended					Three months ended
		September 30,					September 30,
		2014			2013		2014		2013
	REVENUE
	Aquarium and aquarium supplies	$	71,321		$	58,553	$	36,174	$	33,971
	Medical technology		—			—		—		—
	Corporate		—			—		—		—
		$	71,321		$	58,553	$	36,174	$	33,971
	GROSS PROFIT
	Aquarium and aquarium supplies	$	33,586		$	23,677	$	15,722	$	16,903
	Medical technology		—			—		—		—
	Corporate		—			—		—		—
		$	33,586		$	23,677	$	15,722	$	16,903
	GENERAL AND ADMINISTRATIVE EXPENSE
	Aquarium and aquarium supplies	$	59,474		$	51,677	$	31,696	$	8,928
	Corporate		211,457			204,267		109,550		114,260
		$	270,931		$	255,944	$	141,246	$	123,188
	Corporate operating expense includes general and administrative costs not allocated to operating segments.
				30-Sep-14			31-Mar-14
	TOTAL ASSETS
	Aquarium and aquarium supplies			$	9,070		$	24,756
	Medical technology				—			—
	Corporate				21,750			52,989
				$	30,820		$	77,745

General_Organization_and_Busin1

General Organization and Business (Details) (USD $)	3 Months Ended		6 Months Ended		1 Months Ended	6 Months Ended	1 Months Ended	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2012	Sep. 30, 2014	Mar. 31, 2012	Sep. 30, 2014
					Nano3D Biosciences, Inc. ("N3D") [Member]	Nano3D Biosciences, Inc. ("N3D") [Member]	Nano3D Biosciences, Inc. ("N3D") [Member]	TheraKine Ltd. ("TheraKine") [Member]
							Scenario, Plan [Member]
Related Party Transaction [Line Items]	'	'	'	'	'	'	'	'
Shares acquired of joint venture's common stock	'	'	'	'	145	'	604	'
Percentage of outstanding stock acquired	'	'	'	'	'	'	5.00%	'
Common stock, price per share	'	'	'	'	'	'	$413.62	'
Payments to joint venture	'	'	'	'	$60,000	'	$249,826	'
Weekly payments to joint venture	'	'	'	'	'	'	5,000	'
Expenses related to joint ventures and business development activities	$20,000	$48,125	$60,000	$55,000	'	$40,000	'	$20,000

Going_Concern_Details

Going Concern (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Going Concern [Abstract]	'	'	'	'
Net loss	$161,128	$248,577	$536,037	$467,946
Net cash used in operating activities	'	'	206,287	315,003
Negative working capital	$408,184	'	$408,184	'

Summary_of_Significant_Account2

Summary of Significant Accounting Policies (Details) (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014	Mar. 31, 2013
Summary of Significant Accounting Policies [Abstract]	'	'	'	'
Cash and cash equivalents	$17,863	$79,641	$65,373	$84,592
Advertising costs	5,384	6,058	'	'
Potentially issuable shares upon the conversion of convertible notes payable and interest	16,471,845	11,439,232	'	'
Commitments and contingencies	'	'	'	'
Minimum [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Estimated Useful Lives	'3 years	'	'	'
Maximum [Member]	'	'	'	'
Property, Plant and Equipment [Line Items]	'	'	'	'
Estimated Useful Lives	'5 years	'	'	'

Advances_Details

Advances (Details) (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Advances [Abstract]	'	'	'
Proceeds from advances	$143,113	$283,229	'
Refinance of advances into convertible notes payable	292,566	416,685	'
Advances payable	'	'	$149,453

Convertible_Notes_Payable_Sche

Convertible Notes Payable (Schedule of Convertible Notes Payable) (Details) (USD $)	6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Debt Instrument [Line Items]	'	'
Total convertible notes payable	$292,566	$228,827
Less: current portion of convertible notes payable	'	'
Less: discount on noncurrent convertible notes payable	-281,923	-215,716
Convertible Notes Payable, Noncurrent	10,643	13,111
Convertible Note Payable Dated June 30, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	'	4,742
Debt instrument, maturity date	30-Jun-15	'
Debt instrument, issuance date	30-Jun-13	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.04	'
Convertible Note Payable Dated September 30, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	'	224,085
Debt instrument, maturity date	30-Sep-15	'
Debt instrument, issuance date	30-Sep-13	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.04	'
Convertible Note Payable Dated April 1, 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	149,453	'
Debt instrument, maturity date	31-Mar-16	'
Debt instrument, issuance date	1-Apr-14	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.03	'
Convertible Note Payable Dated June 30, 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	62,980	'
Debt instrument, maturity date	30-Jun-16	'
Debt instrument, issuance date	30-Jun-14	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.02	'
Convertible Note Payable Dated September 20, 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Total convertible notes payable	$80,133	'
Debt instrument, maturity date	30-Sep-16	'
Debt instrument, issuance date	30-Sep-14	'
Debt instrument, interest rate	10.00%	'
Debt instrument, conversion price per share	$0.01	'

Convertible_Notes_Payable_Sche1

Convertible Notes Payable (Schedule of Convertible Notes Issued) (Details) (USD $)	6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Debt Instrument [Line Items]	'	'	'
Total convertible notes payable	$292,566	'	$228,827
Beneficial conversion discount on convertible notes	292,566	416,685	'
Maximum ownership percentage allowed after converting	4.99%	'	'
Maximum [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt instrument, conversion price per share	$0.03	'	'
Minimum [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Debt instrument, conversion price per share	$0.01	'	'
Convertible Note Payable Dated April 1, 2014 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Total convertible notes payable	149,453	'	'
Debt instrument, issuance date	1-Apr-14	'	'
Debt instrument, maturity date	31-Mar-16	'	'
Debt instrument, interest rate	10.00%	'	'
Debt instrument, conversion price per share	$0.03	'	'
Convertible Note Payable Dated June 30, 2014 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Total convertible notes payable	62,980	'	'
Debt instrument, issuance date	30-Jun-14	'	'
Debt instrument, maturity date	30-Jun-16	'	'
Debt instrument, interest rate	10.00%	'	'
Debt instrument, conversion price per share	$0.02	'	'
Convertible Note Payable Dated September 20, 2014 [Member]	'	'	'
Debt Instrument [Line Items]	'	'	'
Total convertible notes payable	$80,133	'	'
Debt instrument, issuance date	30-Sep-14	'	'
Debt instrument, maturity date	30-Sep-16	'	'
Debt instrument, interest rate	10.00%	'	'
Debt instrument, conversion price per share	$0.01	'	'

Convertible_Notes_Payable_Conv

Convertible Notes Payable (Conversions to Common Stock) (Details) (USD $)	6 Months Ended
	Sep. 30, 2014
Convertible Note Payable Dated June 30, 2013 [Member]	'
Debt Conversion [Line Items]	'
Amount of note principal converted	$4,742
Amount of note interest converted	212
Debt instrument, conversion price per share	$0.04
Convertible Note Payable Dated September 30, 2013 [Member]	'
Debt Conversion [Line Items]	'
Amount of note principal converted	224,085
Amount of note interest converted	$14,283
Debt instrument, conversion price per share	$0.04

Notes_payable_Details

Notes payable (Details) (Notes Payable to Third Parties [Member], USD $)	6 Months Ended
	Sep. 30, 2014	Mar. 31, 2014
Promissory Note, Dated December 30, 2013 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	$50,000	'
Debt instrument, interest rate	5.00%	'
Debt instrument, frequency of payment	'monthly	'
Debt instrument, term	'4 years	'
Debt instrument, installment payments start date	1-Jan-15	'
Notes payable	49,660	50,000
Promissory Note, Dated September 30, 2014 [Member]	'	'
Debt Instrument [Line Items]	'	'
Debt instrument, face amount	5,000	'
Debt instrument, interest rate	5.00%	'
Debt instrument, frequency of payment	'monthly	'
Debt instrument, term	'26 months	'
Debt instrument, installment payments start date	1-Oct-14	'
Notes payable	$5,000	'

Related_Party_Transactions_Det

Related Party Transactions (Details) (USD $)	Sep. 30, 2014	Mar. 31, 2014
Related Party Transactions [Abstract]	'	'
Related party advances payable	$142,509	$131,505

Stockholders_Equity_Details

Stockholders' Equity (Details) (USD $)	6 Months Ended
	Sep. 30, 2014
Debt Conversion [Line Items]	'
Shares issued for conversion of notes payable	$243,322
Shares issued for conversion of notes payable, shares	6,083,043

Commitments_Details

Commitments (Details) (Office Space, Legal Services, Accounting Services, Fundraising and Management Services [Member], USD $)	6 Months Ended
	Sep. 30, 2014
Office Space, Legal Services, Accounting Services, Fundraising and Management Services [Member]	'
Other Commitments [Line Items]	'
Fees incurred in the period	$95,637
Commitments	$253,177

Business_Segments_Details

Business Segments (Details) (USD $)	3 Months Ended		6 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013	Mar. 31, 2014
Segment Reporting Information [Line Items]	'	'	'	'	'
REVENUE	$36,174	$33,971	$71,321	$58,553	'
GROSS PROFIT	15,722	16,903	33,586	23,677	'
GENERAL AND ADMINISTRATIVE EXPENSE	141,246	123,188	270,931	255,944	'
TOTAL ASSETS	30,820	'	30,820	'	77,745
Aquarium and Aquarium Supplies [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
REVENUE	36,174	33,971	71,321	58,553	'
GROSS PROFIT	15,722	16,903	33,586	23,677	'
GENERAL AND ADMINISTRATIVE EXPENSE	31,696	8,928	59,474	51,677	'
TOTAL ASSETS	9,070	'	9,070	'	24,756
Medical Technology [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
REVENUE	'	'	'	'	'
GROSS PROFIT	'	'	'	'	'
TOTAL ASSETS	'	'	'	'	'
Corporate [Member]	'	'	'	'	'
Segment Reporting Information [Line Items]	'	'	'	'	'
REVENUE	'	'	'	'	'
GROSS PROFIT	'	'	'	'	'
GENERAL AND ADMINISTRATIVE EXPENSE	109,550	114,260	211,457	204,267	'
TOTAL ASSETS	$21,750	'	$21,750	'	$52,989

Subsequent_Events_Details

Subsequent Events (Details) (USD $)	6 Months Ended		1 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Oct. 31, 2014
			Subsequent Event [Member]
Subsequent Event [Line Items]	'	'	'
Conversion of convertible notes and interest into common stock	$243,322	$200,113	$126,000
Conversion of convertible notes and interest into common stock, shares	'	'	4,200,000
Conversion of convertible notes and interest into common stock, price	'	'	$0.03